Author Archives: Sara Agee Le

July 16, 2020
In The News

In 2014, there were an estimated 89 AI-backed companies focused on drug discovery. Now, there are as many as 214.

Read Article
July 9, 2020
In The News

Drug discovery startup Atomwise and stroke risk predictor Viz.ai are among a group of seven healthcare companies recognized by Forbes for their artificial intelligence capabilities.

Read Article
July 7, 2020
In The News

As Covid-19 continues to threaten lives and livelihoods around the world, a great emphasis has been put on preventing and treating the disease. However, putting a human drug through the FDA approval process costs hundreds of millions of dollars and takes months, if not years, of clinical trials. What if one of the over 7,800 […]

Read Article
July 3, 2020
In The News

Artificial intelligence is beginning to be usefully deployed in almost every industry from customer call centers and finance to drug research. Yet the field is also plagued by relentless hype, opaque jargon and esoteric technology making it difficult for outsiders identify the most interesting companies.

Read Article
July 2, 2020
In The News

The quantity of data about medicines, diseases, and biology is growing. So too, are the number of companies that employ artificial intelligence in drug discovery. Most of the low-hanging fruit in drug research has already been picked, and the industry is clamoring to make sense of the new data, according to Jeffrey Lu, CEO and […]

Read Article
June 26, 2020
In The News

The University of Kentucky (UK) has announced a research collaboration with Atomwise to explore potential COVID-19 therapies. An associate professor in UK’s college of medicine was granted the project from Atomwise’s Artificial Intelligence (AI) Molecular Screen award program, which seeks to democratize access to AI for drug discovery and enable researchers to accelerate the translation of their research into novel […]

Read Article